Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HJ891
- Development stage
- Phase 3
- Lead developer
- 成都华健未来科技
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HJ891 is a potent and highly selective small molecule inhibitor of Ubiquitin-Specific Protease 1 (USP1), developed by Chengdu Huajian Future Technology. USP1 is a deubiquitinating enzyme that plays a critical role in the DNA damage response (DDR) pathway, specifically in the deubiquitination of PCNA and FANCD2. By inhibiting USP1, HJ891 disrupts DNA repair mechanisms, leading to genomic instability and cell death in cancer cells, particularly those with existing deficiencies in homologous recombination repair (HRR), such as BRCA1/2 mutations. It is currently being evaluated in Phase 1 clinical trials for the treatment of advanced solid tumors.
02
Targets
USP1 (Ubiquitin-specific protease 1)
Beyond the preview
Go deeper on HJ891.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HJ891.